Compare · JNJ vs ZSTK
JNJ vs ZSTK
Side-by-side comparison of Johnson & Johnson (JNJ) and ZeroStack Corp. (ZSTK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both JNJ and ZSTK operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ carries a market cap of $452.25B.
- JNJ has hit the wire 13 times in the past 4 weeks while ZSTK has been quiet.
- JNJ has more recent analyst coverage (25 ratings vs 0 for ZSTK).
- Company
- Johnson & Johnson
- ZeroStack Corp.
- Price
- $227.47-1.37%
- $7.32+30.71%
- Market cap
- $452.25B
- -
- 1M return
- -5.19%
- -
- 1Y return
- +46.49%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 13
- 0
- Recent ratings
- 25
- 0
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest JNJ
- SEC Form 10-Q filed by Johnson & Johnson
- IMAAVY® (nipocalimab-aahu) shows over two years of sustained disease control in a broad population with generalized myasthenia gravis (gMG)
- Johnson & Johnson to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
- Johnson & Johnson Showcases CARTO-Powered Innovation, Including Debut of CARTOSOUND SONATA, to Advance Arrhythmia Care at HRS 2026
- The Infrastructure Play Hiding in Plain Sight Across Cardiac Care
- Johnson & Johnson to Participate in the Bank of America 2026 Healthcare Conference
- Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
- Johnson & Johnson Announces 64th Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 3.1%
- Johnson & Johnson reports Q1 2026 results, raises 2026 outlook
- Johnson & Johnson Showcases New Clinical Data for TECNIS PureSee IOL at ASCRS 2026 Demonstrating Excellent Contrast Sensitivity and Extended Range of Vision
Latest ZSTK
- SEC Form 4 filed by Heinrich Michael
- Nasdaq-Listed ZeroStack Corp. Makes $107 Million Institutional Commitment To Increase Strategic Position in 0G Token Ecosystem
- ZeroStack Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- ZeroStack Announces $107 Million Cryptocurrency Financing, Elimination of Convertible Note and Plan to Redomicile to Texas
- ZeroStack Corp. Reports 3.2 Million 0G Tokens Earned in Staking Rewards at 22% APY
- ZeroStack Corp. Secures $6.5 Million Order from Major Pharmaceutical Company to Support Distribution in Germany
- SEC Form 10-K filed by ZeroStack Corp.
- ZeroStack Corp. Reports First One Million in 0G Token Staking Rewards at 21% APY